Publication:
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Simple item page
dc.contributor.authorYASİN, Ayşe İrem
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorSÜMBÜL, BİLGE
dc.contributor.authorKORAL, LOKMAN
dc.contributor.authorŞİMŞEK, MELİH
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorOzturk, Akin
dc.contributor.authorPerkin, Perihan
dc.contributor.authorDemirtas, Derya
dc.contributor.authorErdemoglu, Engin
dc.contributor.authorHACIBEKİROĞLU, İLHAN
dc.contributor.authorCakir, Emre
dc.contributor.authorTanrikulu, Eda
dc.contributor.authorCoban, Ezgi
dc.contributor.authorOzcelik, Melike
dc.contributor.authorCelik, Sinemis
dc.contributor.authorTeker, Fatih
dc.contributor.authorAKSOY, ASUDE
dc.contributor.authorFirat, Sedat T.
dc.contributor.authorTekin, Omer
dc.contributor.authorKalkan, Ziya
dc.contributor.authorTurken, Orhan
dc.contributor.authorOven, Bala B.
dc.contributor.authorDane, Faysal
dc.contributor.authorBilici, Ahmet
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorŞEKER, Mesut
dc.contributor.authorTÜRK, HACI MEHMET
dc.contributor.authorGumus, Mahmut
dc.contributor.institutionauthorYASİN, AYŞE İREM
dc.contributor.institutionauthorSÜMBÜL, BİLGE
dc.contributor.institutionauthorŞİMŞEK, MELİH
dc.contributor.institutionauthorŞEKER, MESUT
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2022-02-08T20:59:18Z
dc.date.available2022-02-08T20:59:18Z
dc.date.issued2022-01-01T00:00:00Z
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.pubmed35081732
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30384
dc.identifier.wosWOS:000747186600001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectCoronaVac
dc.subjectSARS-CoV-2
dc.subjectcancer
dc.subjectchemotherapy
dc.subjectimmunotherapy
dc.subjectmalignancy
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
dc.typeArticle
dspace.entity.typePublication
local.avesis.idbbba4845-6058-436d-bb14-f062eeebfebd
local.indexed.atPubMed
local.indexed.atWOS
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublicationdc78f073-a262-42b7-893f-38dcc921fdbb
relation.isAuthorOfPublication51568f47-69f1-46a2-b201-e6d6161080a8
relation.isAuthorOfPublication037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isAuthorOfPublication8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy and safety profile of COVID 19 vaccine in cancer patients a prospective, multicenter cohort study.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Yayınlar - Eserler